The short answer

In 2026, Medicare Part D limits what you pay out of pocket for covered prescriptions to $2,100 a year. Once you reach it, your covered drugs cost $0 for the rest of the year. But the new $50 Medicare GLP-1 Bridge copay is separate — it does not count toward that cap.

This is one of the most important — and most misunderstood — changes for older adults paying for expensive medications. If you take a GLP-1, where your drug fits depends entirely on why it was prescribed. Below is the plain-English version.

What the $2,100 cap actually is

For decades, Medicare Part D had no ceiling on what you could spend out of pocket. The Inflation Reduction Act changed that. In 2025, a hard cap of $2,000 was introduced. For 2026 it rises slightly to $2,100, according to the Kaiser Family Foundation.

The cap applies to your own out-of-pocket spending — deductibles, copays, and coinsurance — on drugs your Part D plan covers. It does not include your monthly premium. Once your out-of-pocket total for the year hits $2,100, you pay nothing more for covered prescriptions until January, when the count resets.

The three payment stages in 2026

The old "donut hole" coverage gap is gone. In 2026, a standard Part D plan moves through three stages:

  1. Deductible — you pay the full negotiated price until you meet your plan's deductible, which can be up to $615 in 2026. Some plans set a lower deductible or none at all.
  2. Initial coverage — you pay your plan's cost-sharing, typically 25% of the drug's cost (or a set copay) on a standard plan.
  3. Catastrophic coverage — once your out-of-pocket spending reaches $2,100, you pay $0 for covered drugs for the rest of the calendar year.

For an inexpensive generic, most people never come close to the cap. For a brand-name GLP-1, it's a different story.

How fast a GLP-1 gets you to the cap

Brand-name GLP-1 medications are expensive — Wegovy, Ozempic, Zepbound, and Mounjaro are often priced over $1,000 a month before insurance. On a standard plan paying 25% coinsurance, that's a few hundred dollars a month in your share. Stacked on top of the deductible, many people taking a covered GLP-1 will reach the $2,100 cap within the first several months of the year — and then pay $0 for that drug, and every other covered drug, through December.

That's the good news the cap delivers: a predictable worst-case number. The catch is that the cap only helps if the drug is covered by your Part D plan in the first place — and for GLP-1s, coverage hinges on the diagnosis.

Where the $50 GLP-1 Bridge fits — and why it doesn't count

As of July 1, 2026, the Medicare GLP-1 Bridge lets eligible members get an FDA-approved GLP-1 for obesity at a flat $50 a month. It sounds like the cheapest path — and often it is — but it works very differently from regular Part D.

The Bridge is a temporary CMS demonstration program administered separately from your Part D plan. Because of that, the $50 you pay each month does not count toward your Part D deductible or your $2,100 out-of-pocket cap (KFF). The money you spend on the Bridge sits outside the standard benefit entirely.

For most people that's fine — $600 a year for the Bridge is still far less than the cap. But it means you can't use Bridge spending to "buy down" the cost of your other prescriptions. One more wrinkle: Extra Help and the Low-Income Subsidy don't apply to the Bridge — the copay stays $50 for everyone, even people who pay little or nothing for their other drugs. Our Bridge cost guide walks through the math.

You can check whether you'd qualify for the Bridge in two minutes with our eligibility quiz.

Diabetes, heart, or sleep apnea: a different (and capped) path

Here's the part that trips people up. Medicare has long been allowed to cover GLP-1s for medical conditions other than obesity — type 2 diabetes (Ozempic, Mounjaro), cardiovascular risk reduction (Wegovy), and moderate-to-severe obstructive sleep apnea with obesity (Zepbound). When a GLP-1 is prescribed and approved for one of those, it runs through your regular Part D plan — which means that spending does count toward your deductible and the $2,100 cap.

So the same drug can take two different routes:

  • For obesity → the $50 Bridge, separate from the cap.
  • For diabetes, heart risk, or sleep apnea → standard Part D, and it counts toward the cap.

If you have one of those conditions, the Part D route may actually be the better deal once you hit the cap, because every covered drug you take afterward also drops to $0. See does Medicare cover Ozempic and our Medicare Advantage GLP-1 coverage guide for how this plays out on different plans.

If the early-year bill is the problem: the monthly payment plan

Even with the $2,100 cap, hitting it in February or March can mean a painful run of large bills early in the year. Medicare's Prescription Payment Plan (sometimes called "M3P"), available since 2025, lets you spread your out-of-pocket Part D costs into smooth monthly payments across the year instead of paying a big lump sum at the pharmacy. You still pay the same $2,100 total — you just don't pay it all at once. Any Part D enrollee can opt in through their plan; it's most useful for people with high drug costs early in the year, exactly like covered GLP-1 users.

What to do next

  1. Find out which path applies to you. If your goal is weight loss and you have Part D, take the eligibility quiz to see if the $50 Bridge is an option.
  2. Ask your plan how your GLP-1 is covered — for which diagnosis, on which tier, and what your share is. That tells you how quickly you'd reach the cap.
  3. If costs hit early, ask about the Prescription Payment Plan to smooth them out.
  4. Don't have a prescriber yet? Find a Medicare-friendly GLP-1 provider near you.

Data note

Figures reflect Medicare Part D rules for 2026 (out-of-pocket cap $2,100; standard deductible up to $615) and the Medicare GLP-1 Bridge demonstration running July 1, 2026 through December 31, 2027. Confirm current amounts and your own coverage with your plan or Medicare.gov. This is educational information, not medical or financial advice.